Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1988-06-23
1989-08-29
Robinson, Douglas W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
514569, 514561, 514567, A61K 3121, A61K 3119, A61K 31195
Patent
active
048617954
ABSTRACT:
Disclosed are pharmaceutical compositions containing naphthoic acid derivatives and method of use for enhancing oxygen availability to mammailian tissue.
REFERENCES:
patent: 3651134 (1972-03-01), Elpern et al.
patent: 3673238 (1972-06-01), Elpern et al.
patent: 4562286 (1985-12-01), Foster
patent: 4626431 (1986-12-01), Batchelor et al.
patent: 4626432 (1986-12-01), Hyde et al.
patent: 4774088 (1988-09-01), Vora
Teisseire et al., "Long-Term Physiological Effects of Enhanced O.sub.2 Release by Inositol Hexaphosphate-Loaded Erythrocytes"; Proc. Natl. Acad. Sci, U.S.A., vol. 84, pp. 6894-6898, Oct. 1987.
Pendelton et al., "Effect of Propranolol Upon the Hemoglobin-Oxygen Dissocation Curve", The Journal of Pharmacology and Experimental Therapeutics, vol. 180, No. 3, pp. 647-656, 1971.
Gross et al., "Effect of Ortho-Iodo Sodium Benzoate on Hemoglobin-Oxygen Affinity in Normal and Ischemic Myocardium", The Journal of Pharmacology and Experimental Therapeutics, vol. 202, pp. 72-81, 1977.
Perutz et al., "Benzafibrate Lowers Oxygen Affinity of Haemoglobin", The Lancet, pp. 881-882.
Hyde et al., "Modification of the Haemoglobin Oxygen Dissociation Curve in Whole Blood by a Compound with Dual Action", The Lancet, pp. 15-16, Jul. 1984.
Patterson et al., "Xanthone Additives for Blood Storage that Maintain Its Potential for Oxygen Delivery", Transfusion, vol. 28, No. 1, pp. 34-37, 1988.
Menard Paul R.
Pendelton Robert G.
Pendley, II Charles E.
Schreiber Alain B.
Suh John T.
Gobrogge Roger
Robinson Douglas W.
Rorer Pharmaceutical Corporation
LandOfFree
Treatment of conditions requiring enhanced oxygen availability t does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of conditions requiring enhanced oxygen availability t, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of conditions requiring enhanced oxygen availability t will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2238609